iANTHUS CAPITAL HOLDINGS (ITHUF) Cost of Revenue (2020 - 2026)
iANTHUS CAPITAL HOLDINGS's (ITHUF) quarterly Cost of Revenue came in at $17.6 million in Q1 2026, down 8.6% year-on-year from $19.2 million in Q1 2025, and down 12.95% quarter-over-quarter from $20.2 million in Q4 2025.
iANTHUS CAPITAL HOLDINGS (ITHUF) Cost of Revenue (2020 - 2026) Analysis & Trends
iANTHUS CAPITAL HOLDINGS has disclosed Cost of Revenue across 7 years of filings, most recently posting $17.6 million for Q1 2026.
- Cost of Revenue for Q1 2026 came in at $17.6 million, down 8.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.6 million (down 12.25% YoY), and the FY2025 annual result was $78.3 million, down 15.32% from the prior year.
- Cost of Revenue came in at $17.6 million for Q1 2026 at iANTHUS CAPITAL HOLDINGS, down from $20.2 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $29.5 million in Q3 2023 to a low of $17.6 million in Q1 2026.
- The 5-year median for Cost of Revenue is $21.5 million (2022), against an average of $22.0 million.
- Across the five-year window, Cost of Revenue advanced 27.39% in 2023 and dropped 24.85% in 2024, its largest moves.
- iANTHUS CAPITAL HOLDINGS's Cost of Revenue stood at $21.5 million in 2022, then increased by 16.2% to $25.0 million in 2023, then retreated by 5.53% to $23.6 million in 2024, then declined by 14.31% to $20.2 million in 2025, then dropped by 12.95% to $17.6 million in 2026.
- The last three Cost of Revenue figures came in at $17.6 million (Q1 2026), $20.2 million (Q4 2025), and $19.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | iANTHUS CAPITAL HOLDINGS | - | - | 15.92 Mn | 17.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.59 Mn |
| Mar 31, 2026 | 17.59 Mn |
| Dec 31, 2025 | 20.21 Mn |
| Dec 31, 2025 | 20.21 Mn |
| Sep 30, 2025 | 19.81 Mn |
| Sep 30, 2025 | 19.81 Mn |
| Jun 30, 2025 | 19.03 Mn |
| Jun 30, 2025 | 19.03 Mn |
| Mar 31, 2025 | 19.24 Mn |
| Mar 31, 2025 | 19.24 Mn |
| Dec 31, 2024 | 23.58 Mn |
| Dec 31, 2024 | 23.58 Mn |
| Sep 30, 2024 | 22.20 Mn |
| Sep 30, 2024 | 22.20 Mn |
| Jun 30, 2024 | 22.31 Mn |
| Jun 30, 2024 | 22.31 Mn |
| Mar 31, 2024 | 24.36 Mn |
| Mar 31, 2024 | 24.36 Mn |
| Dec 31, 2023 | 24.96 Mn |
| Dec 31, 2023 | 24.96 Mn |